Navigation Links
MGC Diagnostics Corporation Completes Sale of New Leaf Business Assets to Life Time - The Healthy Way of Life Company
Date:8/30/2012

SAINT PAUL, Minn., Aug. 30, 2012 /PRNewswire/ -- MGC Diagnostics Corporation (NASDAQ: MGCD), (formerly Angeion Corporation (NASDAQ: ANGN)), a global medical technology company, today announced it has sold the assets of its New Leaf business to Life Time Fitness, Inc. (NYSE: LTM) effective August 28, 2012. Under the transaction, Life Time paid MGC Diagnostics $1.0 million at closing, and will pay an additional $235,000 over the next 18 months.

(Logo: http://photos.prnewswire.com/prnh/20120821/LA60189LOGO)

Gregg O. Lehman, Ph.D., president and chief executive officer of MGC Diagnostics, said, "We are pleased to have completed this sale to Life Time. I believe that as part of Life Time's Healthy Way of Life service offerings, the New Leaf technology will continue to grow and thrive."

Under the transaction, MGC Diagnostics sold Life Time its New Leaf-related software and support materials, New Leaf product inventory, and New Leaf trademarks, service marks, and websites.  The Company also licensed to Life Time certain patents and other intellectual property for use in the general wellness and health and fitness field.  MGC Diagnostics retained all rights to this intellectual property in the medical field.  Finally, MGC Diagnostics and Life Time entered into a Transition and Supply Agreement that runs through June 30, 2014 to transition the New Leaf business to Life Time.

In connection with the transaction, the Company will wind down its non-Life Time New Leaf business.  The Company will continue to provide its existing New Leaf customers, other than Life Time, with products and service under ongoing contractual obligations through June 30, 2014.

The Company expects to recognize revenue and expense associated with its on-going obligations to Life Time under the Transition and Supply Agreement, and expects to incur revenue and expenses from the products and services sold to non-Life Time customers during the period through June 30, 2014.

About Life Time Fitness, Inc.
As The Healthy Way of Life Company, Life Time Fitness (NYSE: LTM) helps organizations, communities and individuals achieve their total health objectives, athletic aspirations and fitness goals by engaging in their areas of interest – or discovering new passions – both inside and outside of Life Time's distinctive and large sports, professional fitness, family recreation and spa destinations, most of which operate 24 hours a day, seven days a week. The Company's Healthy Way of Life approach enables customers to achieve this by providing the best programs, people and places of uncompromising quality and value. As of August 30, 2012, the Company operated 105 centers under the LIFE TIME FITNESS® and LIFE TIME ATHLETIC(SM) brands in the United States and Canada. Additional information about Life Time centers, programs and services is available at lifetimefitness.com.

About MGC Diagnostics
MGC Diagnostics Corporation (NASDAQ: MGCD), (formerly Angeion Corporation), is a global medical technology company dedicated to CardioRespiratory health solutions. MGC Diagnostics develops, manufactures and markets non-invasive diagnostic systems. This portfolio of products provide solutions for disease detection, integrated care, and wellness across the spectrum of CardioRespiratory healthcare. The Company's products are sold internationally through distributors and in the United States through a direct sales force targeting heart and lung specialists located in hospitals, university-based medical centers, medical clinics, physicians' offices, pharmaceutical companies, medical device manufacturers, and clinical research organizations (CROs). For more information about MGC Diagnostics, visit www.mgcdiagnostics.com.

Cautionary Statement Regarding Forward-Looking Statements
From time to time, in reports filed with the Securities and Exchange Commission, in press releases, and in other communications to shareholders or the investing public, MGC Diagnostics Corporation may make forward−looking statements concerning possible or anticipated future financial performance, business activities or plans that include the words "believes," "expects," "anticipates," "intends" or similar expressions.  For these forward−looking statements, the Company claims the protection of the safe harbor for forward−looking statements contained in federal securities laws.  These forward−looking statements are subject to a number of factors, risks and uncertainties, including those disclosed in our periodic filings with the SEC, that could cause actual performance, activities or plans after the date the statements are made to differ significantly from those indicated in the forward−looking statements.  For a list of these factors¸ see the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward Looking Statements," in the Company's Form 10-K for the year ended October 31, 2011, and any updates in subsequent filings on Form 10-Q or Form 8-K under the Securities Exchange Act of 1934.Contact:

Robert M. Wolf

Joe Dorame, Robert Blum, Joe DiazMGC Diagnostics Corporation

Lytham Partners, LLCChief Financial Officer

(602) 889-9700(651) 484-4874

mgcd@lythampartners.com


'/>"/>
SOURCE MGC Diagnostics Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. QBC Diagnostics Awarded GSA Contract
2. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
3. Heightened Awareness, Coupled with Expanding Patient Pool, Stimulates Sleep Apnea Diagnostics and Sleep Services Market, Says Frost & Sullivan
4. Ariosa Diagnostics to Present and Exhibit at the 16th International Conference on Prenatal Diagnosis and Therapy
5. ZINO Society Targets Medical Devices, Healthcare IT and Diagnostics
6. Quest Diagnostics To Speak At The Wells Fargo Securities 2012 Healthcare Conference
7. Breakthrough Prostate Cancer Diagnostics
8. NicOx Signs Worldwide Licensing Agreement With Rapid Pathogen Screening, Inc. For Ophthalmic Diagnostics
9. Frost & Sullivan: Expanding Sample Prep Market Supports Growth Trends in Molecular Diagnostics Markets
10. QIAGEN Unveils Initiative to Create Next-Generation Sequencing Portfolio for use in Clinical Research and Molecular Diagnostics
11. Quest Diagnostics to Release Second Quarter 2012 Financial Results on July 19
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... a medical devices company, is one of five recipients to ... Terry McAuliffe,s office. ivWatch will be receiving the STEM ... to be held at the Science Museum of ... that have made significant contributions to science. ... ivWatch ...
(Date:2/5/2016)... Feb. 5, 2016 ... of the "Global Musculoskeletal Partnering 2010-2016: ... profile to their offering. --> ... of the "Global Musculoskeletal Partnering 2010-2016: ... profile to their offering. --> ...
(Date:2/5/2016)... BEIJING , Feb. 5, 2016 ... ("Dehaier Medical" or the "Company"), which develops, markets ... products in China and ... restructuring plan which aims to concentrate the Company,s ... wearable sleep respiratory business and to focus more ...
Breaking Medicine Technology:
(Date:2/5/2016)... , ... February 05, 2016 , ... Love is in ... in a variety of colors, assortments and packaging. This staple for Valentine’s Day is ... Kullen location. , For Valentine’s Day, not only are long-stem roses available, but ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... franchisees of Popeyes Louisiana Kitchen restaurants, launched the 14th annual “Appetite for a ... and adults with muscular dystrophy, ALS and related diseases that severely limit strength ...
(Date:2/5/2016)... ... 05, 2016 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Tasting Event at the La Gorce Country Club in Miami Beach on March ...
(Date:2/5/2016)... ... February 05, 2016 , ... Give To Cure today announced ... and donate to Give To Cure’s campaign that is crowdfunding clinical trials to help ... and share payments through a smart device. In 2015 alone, Venmo processed $7.5 billion ...
(Date:2/5/2016)... ... 05, 2016 , ... Stuart Bentkover, MD, FACS is thrilled to ... the most effective tattoo removal today, Dr. Bentkover is the only doctor in Central ... the PicoSure has been approved by the Food and Drug Administration (FDA) as a ...
Breaking Medicine News(10 mins):